212 related articles for article (PubMed ID: 35984628)
21. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
Wang M; Schuster SJ; Phillips T; Lossos IS; Goy A; Rule S; Hamadani M; Ghosh N; Reeder CB; Barnett E; Bravo MC; Martin P
J Hematol Oncol; 2017 Nov; 10(1):171. PubMed ID: 29096668
[TBL] [Abstract][Full Text] [Related]
22. Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
Kabadi SM; Byfield SD; LE L; Olufade T
Anticancer Res; 2021 Feb; 41(2):927-936. PubMed ID: 33517299
[TBL] [Abstract][Full Text] [Related]
23. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
24. Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study.
Ghosh N; Emond B; Lafeuille MH; Côté-Sergent A; Lefebvre P; Huang Q
Clin Ther; 2021 Aug; 43(8):1285-1299. PubMed ID: 34332789
[TBL] [Abstract][Full Text] [Related]
25. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
Jain P; Zhao S; Lee HJ; Hill HA; Ok CY; Kanagal-Shamanna R; Hagemeister FB; Fowler N; Fayad L; Yao Y; Liu Y; Moghrabi OB; Navsaria L; Feng L; Nogueras Gonzalez GM; Xu G; Thirumurthi S; Santos D; Iliescu C; Tang G; Medeiros LJ; Vega F; Avellaneda M; Badillo M; Flowers CR; Wang L; Wang ML
J Clin Oncol; 2022 Jan; 40(2):202-212. PubMed ID: 34797699
[TBL] [Abstract][Full Text] [Related]
26. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
Rule S; Dreyling M; Goy A; Hess G; Auer R; Kahl B; Cavazos N; Liu B; Yang S; Clow F; Goldberg JD; Beaupre D; Vermeulen J; Wildgust M; Wang M
Br J Haematol; 2017 Nov; 179(3):430-438. PubMed ID: 28832957
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
[TBL] [Abstract][Full Text] [Related]
28. Postibrutinib outcomes in patients with mantle cell lymphoma.
Martin P; Maddocks K; Leonard JP; Ruan J; Goy A; Wagner-Johnston N; Rule S; Advani R; Iberri D; Phillips T; Spurgeon S; Kozin E; Noto K; Chen Z; Jurczak W; Auer R; Chmielowska E; Stilgenbauer S; Bloehdorn J; Portell C; Williams ME; Dreyling M; Barr PM; Chen-Kiang S; DiLiberto M; Furman RR; Blum KA
Blood; 2016 Mar; 127(12):1559-63. PubMed ID: 26764355
[TBL] [Abstract][Full Text] [Related]
29. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Wang M; Ramchandren R; Chen R; Karlin L; Chong G; Jurczak W; Wu KL; Bishton M; Collins GP; Eliadis P; Peyrade F; Lee Y; Eckert K; Neuenburg JK; Tam CS
J Hematol Oncol; 2021 Oct; 14(1):179. PubMed ID: 34717692
[TBL] [Abstract][Full Text] [Related]
30. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
31. Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.
Zhang Y; Liu P; Cai J; Jing H; Zou L; Huang H; Wu Y; Li W; Zhong L; Jin X; Ye X; Feng R; Zhang H; Zhang L; Lin L; Sun X; Tian Y; Xia Z; Li Z; Huang H; Xia Y; Cai Q
Cancer Med; 2022 Nov; 11(22):4134-4145. PubMed ID: 35438258
[TBL] [Abstract][Full Text] [Related]
32. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
Maddocks K; Christian B; Jaglowski S; Flynn J; Jones JA; Porcu P; Wei L; Jenkins C; Lozanski G; Byrd JC; Blum KA
Blood; 2015 Jan; 125(2):242-8. PubMed ID: 25355819
[TBL] [Abstract][Full Text] [Related]
33. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
[TBL] [Abstract][Full Text] [Related]
34. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
Giné E; de la Cruz F; Jiménez Ubieto A; López Jimenez J; Martín García-Sancho A; Terol MJ; González Barca E; Casanova M; de la Fuente A; Marín-Niebla A; Muntañola A; González-López TJ; Aymerich M; Setoain X; Cortés-Romera M; Rotger A; Rodríguez S; Medina Herrera A; García Sanz R; Nadeu F; Beà S; Campo E; López-Guillermo A
J Clin Oncol; 2022 Apr; 40(11):1196-1205. PubMed ID: 35030036
[TBL] [Abstract][Full Text] [Related]
35. Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study.
Murakami H; Yoshioka T; Moriyama T; Ishikawa T; Makita M; Sunami K
Acta Med Okayama; 2021 Aug; 75(4):461-469. PubMed ID: 34511613
[TBL] [Abstract][Full Text] [Related]
36. Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
Ip A; Petrillo A; Della Pia A; Lee GG; Gill S; Varughese T; Zenreich J; Gutierrez M; Zhang J; Ahn J; Bharani V; Nejad AS; Pascual L; Feldman TA; Leslie LA; Goy AH
Leuk Lymphoma; 2023 Dec; 64(14):2225-2235. PubMed ID: 37740588
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
Matsumoto K; Takayama N; Aisa Y; Ueno H; Hagihara M; Watanabe K; Nakaya A; Chen K; Shimizu T; Tsukada Y; Yamada Y; Nakazato T; Ishida A; Miyakawa Y; Yokoyama K; Nakajima H; Masuda Y; Yano T; Okamoto S;
Int J Hematol; 2015 Jun; 101(6):554-62. PubMed ID: 25783753
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
[TBL] [Abstract][Full Text] [Related]
39. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.
Visco C; Di Rocco A; Evangelista A; Quaglia FM; Tisi MC; Morello L; Zilioli VR; Rusconi C; Hohaus S; Sciarra R; Re A; Tecchio C; Chiappella A; Marin-Niebla A; McCulloch R; Gini G; Perrone T; Nassi L; Pennese E; Stefani PM; Cox MC; Bozzoli V; Fabbri A; Polli V; Ferrero S; Celis MIA; Sica A; Petrucci L; Arcaini L; Rule S; Krampera M; Vitolo U; Balzarotti M
Leukemia; 2021 Mar; 35(3):787-795. PubMed ID: 32782382
[TBL] [Abstract][Full Text] [Related]
40. Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.
Stewart CM; Michaud L; Whiting K; Nakajima R; Nichols C; De Frank S; Hamlin PA; Matasar MJ; Gerecitano JF; Drullinsky P; Hamilton A; Straus D; Horwitz SM; Kumar A; Moskowitz CH; Moskowitz A; Zelenetz AD; Rademaker J; Salles G; Seshan V; Schöder H; Younes A; Tsui DWY; Batlevi CL
Clin Cancer Res; 2022 Jan; 28(1):45-56. PubMed ID: 34615723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]